RELAPSE/RECURRENCE
Clinical trials for RELAPSE/RECURRENCE explained in plain language.
Never miss a new study
Get alerted when new RELAPSE/RECURRENCE trials appear
Sign up with your email to follow new studies for RELAPSE/RECURRENCE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can gentler therapy beat harsh chemo for tough leukemia?
Disease control Recruiting nowThis phase 3 trial tests whether less intense drug combinations can control relapsed or refractory acute myeloid leukemia (AML) as well as high-dose chemotherapy. About 339 adults whose AML has returned or not responded to initial treatment will be randomly assigned to either a l…
Matched conditions: RELAPSE/RECURRENCE
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can mindfulness curb relapse and burnout in peer recovery coaches?
Disease control Recruiting nowThis trial tests whether an 8-week virtual mindfulness program can help substance use peer workers reduce their own relapse risk and burnout. Peer workers—people in recovery who support others with substance use issues—often face high stress. The study compares the mindfulness pr…
Matched conditions: RELAPSE/RECURRENCE
Phase: NA • Sponsor: University of Texas at Austin • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New triple-drug attack aims to wipe out stubborn leukemia
Disease control Recruiting nowThis study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see if the treatment can clear hidden cancer cells from the bone marrow and keep them away.…
Matched conditions: RELAPSE/RECURRENCE
Phase: PHASE2 • Sponsor: Shenzhen University General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC